

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

SECTION 1. IDENTIFICATION

Product identifier : Pembrolizumab Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A
Parque Industrial Vice Presidente José Alencar Aparecida de
Goias – GO, Brazil

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Immune system)
repeated exposure (Oral)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.
H373 May cause damage to organs (Immune system) through
prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-
tion/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/

Pembrolizumab Liquid Formulation

Version 5.10 Revision Date: 28.09.2024 SDS Number: 49549-00026 Date of last issue: 30.09.2023
Date of first issue: 23.01.2015

attention.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Sucrose	57-50-1		≥ 5 -< 10
Pembrolizumab	1374853-91-4	Repr., 1B STOT RE, (Oral)(Immune system) , 1	≥ 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Pembrolizumab Liquid Formulation

Version 5.10 Revision Date: 28.09.2024 SDS Number: 49549-00026 Date of last issue: 30.09.2023
Date of first issue: 23.01.2015

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m ³	ACGIH
Pembrolizumab	1374853-91-4	TWA	450 µg/m ³ (OEB 2)	Internal

- Engineering measures** : Minimize workplace exposure concentrations.
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- Filter type : Particulates type

Hand protection

- Material : Chemical-resistant gloves

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

Remarks	: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Eye protection	: Wear the following personal protective equipment: Safety glasses
Skin and body protection	: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: suspension
Color	: Colorless to pale yellow
Odor	: No data available
Odor Threshold	: No data available
pH	: 5,5
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Components:**Sucrose:**

Acute oral toxicity : LD50 (Rat): 29.700 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Sucrose:**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
-----------------------	---	---

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:**Pembrolizumab:**

Reproductive toxicity - Assessment	:	May damage the unborn child., Based on data from similar materials
------------------------------------	---	--

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Components:**Pembrolizumab:**

Target Organs	:	Immune system
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Pembrolizumab:**

Species	:	Monkey
NOAEL	:	200 mg/kg
Application Route	:	Intravenous
Exposure time	:	180 d
Remarks	:	No significant adverse effects were reported
Species	:	Dog

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

NOAEL	:	200 mg/kg
Application Route	:	Intravenous
Exposure time	:	180 d
Remarks	:	No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Pembrolizumab:**

Inhalation	:	Target Organs: Immune system Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis Remarks: Damage to fetus possible
------------	---	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity**

No data available

Persistence and degradability

No data available

Bioaccumulative potential**Components:****Sucrose:**

Partition coefficient: n-octanol/water	:	Pow: < 1
--	---	----------

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**National List of Carcinogenic Agents for Humans - : Not applicable
(LINACH)Brazil. List of chemicals controlled by the Federal : Not applicable
Police**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATIONRevision Date : 28.09.2024
Date format : dd.mm.yyyy**Further information**Sources of key data used to : Internal technical data, data from raw material SDSs, OECD
compile the Material Safety eChem Portal search results and European Chemicals Agen-
Data Sheet cy, <http://echa.europa.eu/>**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

Pembrolizumab Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.10	28.09.2024	49549-00026	Date of first issue: 23.01.2015

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8